Profile data is unavailable for this security.
About the company
Beijing Sun-Novo Pharmaceutical Research Co Ltd is a China-based company principally engaged in the provision of preclinical and integrated clinical research and development services for pharmaceuticals. The Company's main businesses cover comprehensive research and development services in drug development, generic drug development and consistency assessment. The Company's services mainly comprise drug discovery, pharmacology and pharmacodynamics, pharmacy research, clinical research and bioanalysis. The Company provides services in pharmacological research, including raw drugs preparation process and structure confirmation, dosage selection, medical services, operational services, data management and statistical analysis services, risk management services and quality management. The Company mainly conducts its businesses in the domestic market.
- Revenue in CNY (TTM)1.16bn
- Net income in CNY221.37m
- Incorporated2009
- Employees1.39k
- LocationBeijing Sun-Novo Pharmaceutical Research Co Ltd1F, Building 7, No. 79Shuangying West Road, Science ParkChangping DistrictBEIJING 102200ChinaCHN
- Phone+86 1 060748199
- Fax+86 1 060748199
- Websitehttp://sun-novo.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qingdao Vland Biotech INC | 1.26bn | 66.23m | 3.52bn | 1.57k | 52.84 | 2.04 | -- | 2.78 | 0.2631 | 0.2631 | 5.02 | 6.83 | 0.425 | 3.78 | 3.76 | 805,143.80 | 3.25 | 5.78 | 5.09 | 7.89 | 44.98 | 46.13 | 7.65 | 10.34 | 0.9248 | 11.63 | 0.2904 | 33.59 | 3.07 | 8.05 | 15.56 | -0.6507 | 24.68 | -6.89 |
| Hinova Pharmaceuticals Inc | 109.74k | -210.18m | 3.59bn | 179.00 | -- | 2.92 | -- | 32,725.49 | -2.12 | -2.12 | 0.0011 | 12.44 | 0.00007 | 7.12 | 0.0805 | 613.07 | -14.10 | -31.86 | -15.71 | -37.18 | -450.31 | -- | -191,529.30 | -25,578.24 | 6.38 | -- | 0.0457 | -- | -100.00 | -- | 2.44 | -- | 124.37 | -- |
| Bide Pharmatech Co Ltd | 1.10bn | 80.03m | 4.20bn | 846.00 | 51.49 | 2.10 | -- | 3.83 | 0.8983 | 0.8983 | 12.25 | 21.98 | 0.4608 | 0.9359 | 4.51 | 1,298,144.00 | 3.34 | -- | 3.82 | -- | 40.11 | -- | 7.25 | -- | 4.59 | -- | 0.0492 | -- | 30.94 | -- | -24.94 | -- | -- | -- |
| Shanghai Aladdin Biochemical Tech Co Ltd | 497.71m | 103.71m | 4.36bn | 566.00 | 35.39 | 4.19 | -- | 8.76 | 0.4439 | 0.4439 | 1.98 | 3.75 | 0.3103 | 0.3818 | 9.08 | 879,345.60 | 7.20 | 8.83 | 8.22 | 9.61 | 61.57 | 61.49 | 23.21 | 26.85 | 3.10 | 113.47 | 0.2781 | 45.71 | 6.55 | 19.36 | -7.48 | 9.95 | 31.41 | -- |
| Jiangsu Yahong Meditech Co Ltd | 149.71m | -403.23m | 4.41bn | 394.00 | -- | 2.12 | -- | 29.47 | -0.7074 | -0.7074 | 0.2627 | 3.65 | 0.0598 | 16.64 | 6.92 | 379,971.80 | -16.14 | -15.80 | -17.15 | -16.48 | 78.63 | 55.32 | -269.87 | -9,445.91 | 8.97 | -- | 0.0599 | -- | 52,594.79 | -- | -62.42 | -- | 64.28 | -- |
| Beijing Kawin Technol Sha-hld Co Ltd | 1.42bn | 134.34m | 4.61bn | 584.00 | 33.01 | 2.48 | -- | 3.25 | 0.8175 | 0.8175 | 8.53 | 10.87 | 0.5736 | 1.80 | 3.27 | 2,431,971.00 | 6.49 | 5.31 | 8.52 | 6.76 | 81.80 | 86.02 | 11.31 | 8.10 | 2.91 | -- | 0.141 | 43.82 | 21.73 | 14.87 | 39.71 | 21.04 | 25.01 | -- |
| Beijing Sun-Novo Pharma Research Co Ltd | 1.16bn | 221.37m | 4.79bn | 1.39k | 21.62 | 4.23 | -- | 4.14 | 1.98 | 1.98 | 10.33 | 10.10 | 0.6079 | 35.95 | 1.77 | 844,377.10 | 11.25 | 12.99 | 18.76 | 21.70 | 53.30 | 53.93 | 18.50 | 21.34 | 1.86 | 29.92 | 0.3068 | 10.74 | 37.76 | 47.22 | 18.08 | 54.90 | 34.77 | -- |
| HitGen Inc | 423.87m | 52.55m | 5.08bn | 452.00 | 96.47 | 3.69 | -- | 11.99 | 0.1314 | 0.1314 | 1.06 | 3.44 | 0.248 | 7.10 | 4.55 | 937,755.30 | 2.99 | 4.63 | 3.16 | 5.10 | 51.23 | 58.89 | 12.05 | 20.66 | 16.15 | 38.23 | 0.1391 | 19.14 | 12.64 | 19.69 | 61.16 | -1.96 | -6.12 | -- |
| Shanghai Medicilon Inc | 984.17m | -276.79m | 5.11bn | 2.42k | -- | 2.17 | -- | 5.19 | -2.01 | -2.01 | 7.23 | 17.46 | 0.3029 | 6.90 | 1.27 | 378,525.60 | -8.52 | 9.34 | -10.66 | 11.73 | 0.6443 | 36.71 | -28.12 | 14.93 | 2.64 | -- | 0.1147 | 20.18 | -17.68 | 33.26 | -109.82 | -- | 23.60 | -- |
| GemPharmatech Co Ltd | 677.34m | 139.41m | 5.63bn | 1.51k | 40.00 | 2.64 | -- | 8.30 | 0.343 | 0.343 | 1.65 | 5.20 | 0.2703 | 4.54 | 2.06 | 449,761.40 | 5.56 | 9.45 | 6.39 | 11.13 | 63.04 | 70.21 | 20.58 | 28.16 | 4.74 | -- | 0.0509 | 14.68 | 20.45 | 63.48 | -3.48 | -- | 141.38 | -- |
| InventisBio Co Ltd | 77.51m | -348.02m | 6.17bn | 221.00 | -- | 3.56 | -- | 79.61 | -0.6064 | -0.6064 | 0.1346 | 3.01 | 0.0383 | -- | 0.5855 | 350,739.20 | -17.19 | -- | -18.36 | -- | 90.80 | -- | -448.98 | -- | -- | -- | 0.0138 | -- | -- | -- | 41.26 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Beijing Sun-Novo Pharmaceutical Research Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
25.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 7.93m | 9.77% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2024 | 4.97m | 6.12% |
| Essence Fund Co., Ltd.as of 30 Jun 2024 | 3.36m | 4.14% |
| Great Wall Fund Management Co., Ltd.as of 30 Jun 2024 | 1.64m | 2.02% |
| E Fund Management Co., Ltd.as of 30 Sep 2024 | 1.27m | 1.56% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 1.02m | 1.26% |
| Invesco Hong Kong Ltd.as of 30 Sep 2024 | 281.60k | 0.35% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2024 | 168.00k | 0.21% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 137.16k | 0.17% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2024 | 120.17k | 0.15% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
